On May 20, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, reported the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and a member of Ernexa’s Board of Directors.
 
As part of the segment, Dr. Ratner discusses ovarian cancer, one of the most difficult malignancies to treat, and highlights the significant challenges patients continue to face throughout diagnosis and treatment. The discussion explores limitations of current therapeutic approaches and the persistent unmet need for more effective and durable treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Ratner also discusses the evolving ovarian cancer treatment landscape and shares her perspective on Ernexa’s differentiated biological approach to addressing immunologically "cold" tumors. The segment highlights Ernexa’s lead product candidate, ERNA-101, and recently announced preclinical data demonstrating complete tumor elimination and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade.

The discussion also highlights the potential advantages of Ernexa’s engineered allogeneic induced mesenchymal stem cell (iMSC) platform, including the opportunity to develop scalable, off-the-shelf cell therapies designed to improve accessibility and overcome manufacturing challenges associated with traditional autologous approaches.

The Virtual Investor KOL Connect segment featuring Ernexa Therapeutics is now available here. For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

(Press release, Ernexa Therapeutics, MAY 20, 2026, View Source [SID1234665911])

On May 20, 2026 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, reported that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper) on Tuesday, May 26, 2026, at 9:30 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcast will be archived for a limited time following the presentation.

(Press release, Protara Therapeutics, MAY 20, 2026, View Source [SID1234665896])

On May 20, 2026 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, reported it will participate in the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 7th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 27, 2026, at 1:00 p.m. ET.
Jefferies Global Healthcare Conference in New York, NY with a fireside chat on Thursday, June 4, 2026, at 9:20 a.m. ET.
Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Monday, June 8, 2026, at 2:00 p.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time.

(Press release, Syndax, MAY 20, 2026, View Source [SID1234665897])

On May 20, 2026 JSR reported Business Status Briefing FY2025 Full-Year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, JSR, MAY 20, 2026, View Source [SID1234669284])

On May 20, 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper) on Wednesday, May 27, 2026, at 11:00 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

(Press release, Whitehawk Therapeutics, MAY 20, 2026, View Source [SID1234665900])